Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

Background A minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even when these activated effector cells are released fr...

Full description

Bibliographic Details
Main Authors: Reno Debets, Edwin A. Basak, Daan P. Hurkmans, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Ron H. N. van Schaik, Cor H. van der Leest, Nina Schepers, Esther Oomen-De Hoop, Samira El Bouazzaoui
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000586.full

Internet

https://jitc.bmj.com/content/8/1/e000586.full

Similar Items